Factors Promoting Tumor Angiogenesis

References

• Goldman E. The growth of malignant disease in man and the lower animals. Lancet 1907; 2: 1236–1240
   Google Scholar
• Lewis W H. The vascular patterns of tumors. Johns Hopkins Hosp Bull 1927; 41: 156–171
   Google Scholar
• Ide A G, Baker N H, Warren S L. Vascularization of the Brown-Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am J Roentgenol Radiother 1939; 42: 391–899
   Google Scholar
• Algire G H, Chalkley H W, Legallais F Y, et al. Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 1945; 6: 73–85
   Web of Science ®Google Scholar
• Bierman H R, Kelly K H, Dod K S, et al. Studies on the blood supply of tumors in man. I. Fluorescence of cutaneous lesions. J Natl Cancer Inst 1950; 11: 877–887
   Web of Science ®Google Scholar
• Burrows H. The permeability of the blood vessels in and around grafted Jensen rat sarcoma. Am J Cancer 1939; 18: 383–387
   Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182–1186
   PubMed Web of Science ®Google Scholar
• Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue?. Cancer Res 1986; 46: 467–473
   PubMed Web of Science ®Google Scholar
• Fohan J, Klagsburn M. Angiogenic factors. Science 1987; 235: 442–447
   PubMed Web of Science ®Google Scholar
• Follcman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 1990; 82: 4–6
   PubMed Web of Science ®Google Scholar
• Folkman J. The role of anaiogenesis in tumor growth. Semin Cancer Biol 1992; 3: 65–71
   PubMedGoogle Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353–364
   PubMed Web of Science ®Google Scholar
• Amore D PA, Shima D T. Tumor angiogenesis: a physiological process or genetically determined?. Cancer Met Rev 1996; 15: 205–212
   PubMed Web of Science ®Google Scholar
• Liotta L A, Kleinennan J, Saidel G M. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary me-tastases following tumor implantation. Cancer Res 1974; 34: 997–1004
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis and breast cancer. J Clin Oncol 1994; 12: 441–443
   PubMed Web of Science ®Google Scholar
• Weidner N, Semple J P, Welch W R, et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1–8
   PubMed Web of Science ®Google Scholar
• Macchiarini P, Fontanini G, Hardin M J, et al. Relation of neo-vascularization to metastasis of non-small-cell lung cancer. Lancet 1992; 340: 145–146
   PubMed Web of Science ®Google Scholar
• Weidner N, Carroll P R, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401–409
   PubMed Web of Science ®Google Scholar
• Tanigawa N, Matsumura M, Amaya H, et al. Tumor vascularity correlates with the prognosis of patients with esophageal squamous cell carcinoma. Cancer 1997; 79: 220–225
   PubMed Web of Science ®Google Scholar
• Dickinson A J, Fox S B, Persad J, et al. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 1994; 74: 762–766
   PubMedGoogle Scholar
• Jaeger T M, Weidner N, Chew K, et al. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol 1995; 154: 69–71
   PubMed Web of Science ®Google Scholar
• Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84: 1875–1887
   PubMed Web of Science ®Google Scholar
• Horak E R, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992; 340: 1120–1124
   PubMed Web of Science ®Google Scholar
• Srivastava A, Laidler P, Davies R P, et al. The prognostic significance of tumor vascularity in intermediate-thickness (0.76–4.0 mm thick) skin melanoma. Am J Pathol 1988; 133: 419–423
   PubMed Web of Science ®Google Scholar
• Wakui S, Furusato M, Itoh T, et al. Tumor angiogenesis in pros-tatic carcinoma with and without bone marrow metastasis: a morphometric study. J Pathol 1992; 168: 257–262
   PubMed Web of Science ®Google Scholar
• Vesalainen S, Lipponen P, Talja M, et al. Tumor vascularity and basement membrane structure as prognostic factors in T1–2MO prostatic adenocarcinoma. Anticancer Res 1994; 14: 709–714
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Kitadai Y, Bucana C D, et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55: 3964–3968
   PubMed Web of Science ®Google Scholar
• Tanigawa N, Amaya H, Matsumura M, et al. Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas. Cancer Res 1996; 56: 2671–2676
   PubMed Web of Science ®Google Scholar
• Leek R D, Lewis C E, Whitehouse R, et al. Association of macro-phage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996; 56: 4625–4629
   PubMed Web of Science ®Google Scholar
• Meininger C J, Zetter B R. Mast cells and angiogenesis. Semin Cancer Biol 1992; 3: 73–79
   PubMedGoogle Scholar
• Polverini P J, Leibovich S J. Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab Invest 1984; 51: 635–642
   PubMed Web of Science ®Google Scholar
• Xiong M, Elson G, Legarda D, et al. Production of vascular endothelial growth factor by murine macrophages regulation by hypoxia, lactate, and inducible nitric oxide synthase pathway. Am J Pathol 1998; 153: 587–598
   PubMed Web of Science ®Google Scholar
• Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995; 36: 127–137
   PubMed Web of Science ®Google Scholar
• Dvorak H F, Brown L F, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyper-permeability, and angiogenesis. Am J Pathol 1995; 146: 1029–1039
   PubMed Web of Science ®Google Scholar
• Neufeld G, Tessler S, Gitay-Goren H, et al. Vascular endothelial growth factor and its receptors. Prog Growth Factor Res 1994; 5: 89–97
   PubMedGoogle Scholar
• Pepper M S, Mandriota S J, Vassalli J-D, . Angiogenesis-reg-ulating cytokines: activities and interactions. Attempts to Understand Metastasis Formation II, U Gunthert, W Birchmeier, et al. Berlin Springer Verlag, New York 1996; Vol. 213/II: 31–67
   Google Scholar
• Brown J M, Giaccia A J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58: 1408–1416
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Cleary K R, Mai M, et al. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res 1996; 2: 1679–1684
   PubMed Web of Science ®Google Scholar
• Kim K J, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841–844
   PubMed Web of Science ®Google Scholar
• Ferrara N, Henzel W J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161: 851–858
   PubMed Web of Science ®Google Scholar
• Berse B, Brown L F, Van De Water L, et al. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992; 3: 211–220
   PubMed Web of Science ®Google Scholar
• Taichman N S, Cruchley A T, Fletcher L M, et al. Vascular endothelial growth factor in normal human salivary glands and saliva: a possible role in the maintenance of mucosal homeostasis. Lab Invest 1998; 78: 869–875
   PubMed Web of Science ®Google Scholar
• Houck K A, Ferrara N, Winer J, et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991; 5: 1806–1814
   PubMed Web of Science ®Google Scholar
• Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. J Biol Chem 1991; 266: 11947–11954
   PubMed Web of Science ®Google Scholar
• Soker S, Fidder H, Neufeld G, et al. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J Biol Chem 1996; 271: 5761–5767
   PubMed Web of Science ®Google Scholar
• Minchenko A, Bauer T, Salceda S, et al. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest 1994; 71: 374–379
   PubMed Web of Science ®Google Scholar
• Shweiki D, Neeman M, Itin A, et al. Inductiorl of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci USA 1995; 92: 768–772
   PubMed Web of Science ®Google Scholar
• Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843–845
   PubMed Web of Science ®Google Scholar
• Plate K H, Breier G, Weich H A, et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 359: 845–848
   PubMed Web of Science ®Google Scholar
• Forsythe J A, Jiang B-H, Iyer N V, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604–4613
   PubMed Web of Science ®Google Scholar
• Ikeda E, Achen M G, Breier G, et al. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endo-thelial growth factor in C6 glioma cells. J Biol Chem 1995; 270: 19761–19766
   PubMed Web of Science ®Google Scholar
• Levy A P, Levy N S, Goldberg M A. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 1996; 271: 2746–2753
   PubMed Web of Science ®Google Scholar
• Liu Y, Cox S R, Morita T, et al. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Circ Res 1995; 77: 638–643
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay D, Tsiokas L, Zhou X-M, et al. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 1995; 375: 577–581
   PubMed Web of Science ®Google Scholar
• Jiang B-H, Agani F, Passaniti A, et al. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIG-1 in tumor progression. Cancer Res 1997; 57: 5328–5335
   PubMed Web of Science ®Google Scholar
• Koura A N, Liu W, Kitadai Y, et al. Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by cell density. Cancer Res 1996; 56: 3891–3894
   PubMed Web of Science ®Google Scholar
• Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995; 55: 4575–4580
   PubMed Web of Science ®Google Scholar
• Grugel S, Finkenzeller G, Weindel K, et al. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NM 3T3 cells. J Biol Chem 1995; 270: 25915–25919
   PubMed Web of Science ®Google Scholar
• Larcher F, Robles Al, Duran H, et al. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res 1996; 56: 5391–5396
   PubMed Web of Science ®Google Scholar
• Volpert O V, Dameron K M, Bouck N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 1997; 14: 1495–1502
   PubMed Web of Science ®Google Scholar
• Kieser A, Weich H A, Braudner G, et al. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994; 9: 963–969
   PubMed Web of Science ®Google Scholar
• Siemeister G, Weindel K, Mobrs K, et al. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 1996; 56: 2299–2301
   PubMed Web of Science ®Google Scholar
• Finkenzeller G, Marme D, Weich H A, et al. Platelet-derived growth factor-induced transcription of the vascular endothelial growth factor gene is mediated by protein kinase C. Cancer Res 1992; 52: 4821–4823
   PubMed Web of Science ®Google Scholar
• Finkenzeller G, Sparacio A, Technau A, et al. Spl recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. Oncogene 1997; 15: 669–676
   PubMed Web of Science ®Google Scholar
• Detmar M, Yeo K-T, Nagy J A, et al. Keratinocyte-derived vascular permeability factor (vascular endotbelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J Invest Dermatol 1995; 105: 44–50
   PubMed Web of Science ®Google Scholar
• Ben-Av P, Crofford L J, Wilder R L, et al. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin- 1995 1, a potential mechanism for inflammatory angiogenesis. FEBS Lett, 372: 33–87
   PubMedGoogle Scholar
• Dolecki G J, Connolly D T. Effects of a variety of cytokines and inducing agents on vascular permeability factor mRNA levels in U937 cells. Biochem Biophys Res Commun 1901; 180: 572–578
   Google Scholar
• Tsai J-C, Goldman C K, Gillespie G Y. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg 1995; 82: 864–873
   PubMed Web of Science ®Google Scholar
• Cohen T, Nahari D, Cerem L W, et al. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996; 271: 736–741
   PubMed Web of Science ®Google Scholar
• Akagi Y, Liu W, Zebrowski B, et al. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res 1998; 58: 4008–4014
   PubMed Web of Science ®Google Scholar
• Silvagno F, Follenzi A, Arese M, et al. In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth factor molecule promotes angiogenesis. Arterioscler Thromb Vasc Biol 1995; 15: 1857–1865
   PubMed Web of Science ®Google Scholar
• Hyder S M, Stancel G M, Chiappetta C, et al. Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Res 1996; 56: 3954–3960
   PubMed Web of Science ®Google Scholar
• Cullinan-Bove K, Koos R D. Vascular endothelial growth factor/ vascular permeability factor expression in the rat uterus: rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology 1993; 133: 829–837
   PubMed Web of Science ®Google Scholar
• Banerjee S K, Sarkar D K, De A, et al. Effect of estrogen on expression of vascular endothelial growth factor (VEGF) during estrogen-induced pituitary angiogenesis in Rat. Proc Am Assoc Cancer Res 1996; 37: 222
   Google Scholar
• Joseph I BJK, Isaacs J T. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res 1997; 57: 1054–1057
   PubMed Web of Science ®Google Scholar
• Hyder S M, Murthy L, Stancel G M. Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res 1998; 58: 392–395
   PubMed Web of Science ®Google Scholar
• Kuroki M, Beerepoot L V, Voest E E, et al. Regulation of VEGF mRNA expression by reactive oxygen intermediates. Invest Ophthalmol Visual Sci 1995; 36: S895
   Web of Science ®Google Scholar
• Plate K H, Breier G, Risau W. Molecular mechanisms of development and tumor angiogenesis. Brain Pathol 1994; 4: 207–218
   PubMed Web of Science ®Google Scholar
• Leung D W, Cachianes G, Kuang W-J, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306–1309
   PubMed Web of Science ®Google Scholar
• Pepper M S, Ferrara N, Orci L, et al. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991; 181: 902–906
   PubMed Web of Science ®Google Scholar
• Unemori E N, Ferrara N, Bauer E A, et al. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1992; 153: 557–562
   PubMed Web of Science ®Google Scholar
• Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995; 1: 1024–1028
   PubMed Web of Science ®Google Scholar
• Nor J E, Christenseu J, Mooney D J, et al. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced cell survival and induction of Bcl-2 expression. Am J Patliol 1999; 154: 375–384
   PubMed Web of Science ®Google Scholar
• Ku D D, Zaleski J K, Liu S, et al. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol 1993; 265: H586–H592
   PubMed Web of Science ®Google Scholar
• Dvorak H F, Orenstein N S, Carvalho A C, et al. Induction of fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J Immunol 1979; 122: 166–174
   PubMed Web of Science ®Google Scholar
• Senger D R, Galli S J, Dvorak A M, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983–985
   PubMed Web of Science ®Google Scholar
• Dvorak H F, Detmar M, Claffey K P, et al. Vascular permeability factodvascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol 1995; 107: 233–235
   PubMed Web of Science ®Google Scholar
• Yeo K-T, Wang H H, Nagy J A, et al. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res 1993; 53: 2912–2918
   PubMed Web of Science ®Google Scholar
• Nagy J A, Masse E M, Herzberg K T, et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperper-meability, and ascites fluid accumulation. Cancer Res 1995; 55: 360–368
   PubMed Web of Science ®Google Scholar
• Luo J C, Yamaguchi S, Shinkai A, et al. Significant expression of vascular endothelial growth factodvascular permeability factor in mouse ascites tumors. Cancer Res 1998; 58: 2652–2660
   PubMed Web of Science ®Google Scholar
• Nguyen L S, Villablanca A C, Rutledge J C. Substance Pincreases microvascular permeability via nitric oxide-mediated convective pathways. Am J Physiol 1995; 268: R1060–R1068
   PubMed Web of Science ®Google Scholar
• Laszlo F, Whittle B JR, Evans S M, et al. Association of micro-vascular leakage with induction of nitric oxide synthase: effects of nitric oxide synthase inhibitors in various organs. Eur J Pharmacol 1995; 283: 47–53
   PubMed Web of Science ®Google Scholar
• van der Zee R, Murohara T, Luo Z, et al. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation 1997; 95: 1030–1037
   PubMed Web of Science ®Google Scholar
• Roberts W G, Palade G E. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995; 108: 2369–2379
   PubMed Web of Science ®Google Scholar
• Yeo T-K, Dvorak H F. Tumor stroma. Diagnostic Immunopa-thology, R B Colvin, A K Bhan, T McCluskey. Raven Press, New York 1995; 685–697
   Google Scholar
• Yoshiji H, Harris S R, Thorgeirsson U P. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 1997; 57: 3924–3928
   PubMed Web of Science ®Google Scholar
• Terman B I, Carrion M, Kovacs E, et al. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Onco-gene 1991; 6: 1677–1683
   Google Scholar
• Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to fms family. Oncogene 1990; 5: 519–524
   PubMed Web of Science ®Google Scholar
• De Vries C, Escobedo J A, Ueno H, et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989–991
   PubMed Web of Science ®Google Scholar
• Merenmies J, Parada L F, Henkerneyer M. Receptor tyrosine kinase signaling in vascular development. Cell Growth Differ 1997; 8: 3–10
   PubMedGoogle Scholar
• Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. Different signal transduction properties of KDR and Fltl, two receptors for vascular endothelial growth factor. J Biol Chem 1994; 269: 26988–26995
   PubMed Web of Science ®Google Scholar
• Keyt B A, Nguyen H V, Berleau L T, et al. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. J Biol Chem 1996; 271: 5638–5646
   PubMed Web of Science ®Google Scholar
• Shalaby F, Rossant J, Yamaguchi T P, et al. Failure of blood-island formation and vasculogenesis in Flk-l -deficient mice. Nature 1995; 376: 62–66
   PubMed Web of Science ®Google Scholar
• Risau W, Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol 1995; 11: 73–91
   PubMed Web of Science ®Google Scholar
• Brekken R A, Huang X, King S W, et al. Vascular epithelial growth factor as a marker of tumor epithelium. Cancer Res 1998; 58: 1952–1959
   PubMed Web of Science ®Google Scholar
• Millauer B, Longhi M P, Plate K H, et al. Dominant-negative inhibition of Flk-l suppresses the growth of many tumor types in vivo. Cancer Res 1996; 56: 1615–1620
   PubMed Web of Science ®Google Scholar
• Brown L F., Berse B, Jackman R W, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995; 26: 86–91
   PubMed Web of Science ®Google Scholar
• Presta L G, Chen H, O'Connor S J, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593–4599
   PubMed Web of Science ®Google Scholar
• Oku T, Tjuvajev J G, Miyagawa T, et al. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res 1998; 58: 4185–4192
   PubMed Web of Science ®Google Scholar
• Zhu Z, Rockwell P, Lu D, et al. Inhibition of vascular endothelid growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. Cancer Res 1998; 58: 3209–3214
   PubMed Web of Science ®Google Scholar
• Luo J C, Toyoda M, Shibuya M. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res 1998; 58: 2594–2600
   PubMed Web of Science ®Google Scholar
• Bouvet M, Ellis L M, Nishizaki M, et al. Adenovirus-mediated wild-type p53 gene transfer downregulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 1998; 58: 2288–2292
   PubMed Web of Science ®Google Scholar
• Lin P, Sankar S, Shan S-Q, et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 1998; 9: 49–58
   PubMedGoogle Scholar
• Hicklin D J, Pytowski B, Rockwell P, et al. Monoclonal anti-vascular endothelial growth factor (VEGF) receptor (KDR) antibodies which are inhibitors of VEGF binding and antagonists of VEGF-stimulated signaling and growth of human endothelial cells. Proc Am Assoc Cancer Res 1998; 39: 96
   Google Scholar
• Vajkoczy P, Menger M D, Vollmar B, et al. Effect of the FLK-1 antagonist SU5416 on tumor growth, angiogenesis and micro-hemodynamics. Proc Am Assoc Cancer Res 1998; 39: 96, (abstract).
   Google Scholar
• Parry T J, Bouhana K, Gallegos A M, et al. Antitumor and anti-metastatic efficacy of a ribozyme targeting Flt-1 VEGF receptor mRNA. Proc Am Assoc Cancer Res 1998; 39: 96
   Google Scholar
• Wood J, Buchdunger E, Cozens R, et al. Pharmacological profile of a potent and orally active inhibitor of VEGF receptor tyrosine kinases. Proc Am Assoc Cancer Res 1998; 39: 96–97
   Google Scholar
• Kamiya K, Konno H, Tanaka T, et al. Antitumor effect of VEGF neutralizing antibody on the human gastric cancer. Induction of apoptosis. Proc Am Assoc Cancer Res 1998; 39: 44
   Google Scholar
• Matsumoto K, Konno H, Tanaka T, et al. Antitumor effect of combination treatment with VEGF neutralizing antibody and mitromycin C on the human gastric cancer. Roc Am Assoc Cancer Res 1998; 39: 44
   Google Scholar
• Mesiano S, Ferrara N, Jaffe R B. Role of vascular endothelial growth factor in ovarian cancer. Am J Pathol 1998; 153: 1249–1256
   PubMed Web of Science ®Google Scholar
• Im S-A, Gomez-Manzano C, Fueyo J, et al. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res 1999; 59: 895–900
   PubMed Web of Science ®Google Scholar
• Klagsburn M. Angiogenesis and cancer. Cancer Res 1999; 59: 487–490
   PubMedGoogle Scholar
• Nguyen J T, Wu P, Clouse M E, et al. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res 1998; 58: 5673–5677
   PubMed Web of Science ®Google Scholar
• Maglione D, Gueniero V, Viglietto G, et al. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 1991; 88: 9267–9271
   PubMed Web of Science ®Google Scholar
• Hauser S, Weich H A. A heparin-binding form of placenta growth factor (PIGF-2) is expressed in human umbilical vein endothelial cells and in placenta. Growth Factors 1993; 9: 259–268
   PubMed Web of Science ®Google Scholar
• Relf M, LeJeune S, Scott P AE, et al. Expression of the angio-genic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963–969
   PubMed Web of Science ®Google Scholar
• Takahashi A, Sasaki H, Kim S J, et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994; 54: 4233–4237
   PubMed Web of Science ®Google Scholar
• Viglietto G, Maglione D, Rambaldi M, et al. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PIGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 1995; 11: 1569–2579
   PubMed Web of Science ®Google Scholar
• Ziche M, Maglione D, Ribatti D, et al. Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab Invest 1997; 76: 517–531
   PubMed Web of Science ®Google Scholar
• Terman B I, Khandke L, Dougher-Vermazan M, et al. VEGF receptor subtypes KDR and FCT1 show different sensitivities to heparin and placenta growth factor. Growth Factors 1994; 11: 187–195
   PubMed Web of Science ®Google Scholar
• Sawano A, Takahashi T, Yamaguchi S, et al. Flt-1 but not KDR/ Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ 1996; 7: 213–221
   PubMedGoogle Scholar
• Park J E, Chen H H, Winer I, et al. Placenta growth factor. J Biol Chem 1994; 269: 25646–25654
   PubMed Web of Science ®Google Scholar
• Birkenhager R, Schneppe B, Rockl W, et al. Synthesis and physiological activity of heterodimers comprising different splice forms of vascular endothelial growth factor and placenta growth factor. Biochem J 1996; 316: 703–707
   PubMed Web of Science ®Google Scholar
• Cao Y, Chen H, Zhou L, et al. Heterodimers of placenta growth factor/vascular endothelial growth factor. J Biol Chem 1996; 271: 3154–3162
   PubMed Web of Science ®Google Scholar
• DiSalvo J, Bayne M L, Conn G, et al. Purification and characterization of a naturally occurring vascular endothelial growth factor-placenta growth factor heterodimer. J Biol Chem 1995; 270: 7717–7723
   PubMed Web of Science ®Google Scholar
• Grimmond S, Lagercrantz I, Drinkwater C, et al. Cloning andrd56t characterization of a novel human gene related to vascular endothelial growth factor. Genome Res 1996; 6: 124–131
   PubMed Web of Science ®Google Scholar
• Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996; 15: 290–298
   PubMed Web of Science ®Google Scholar
• Lee J, Gray A, Yuan J, et al. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA 1996; 93: 1988–1992
   PubMed Web of Science ®Google Scholar
• Olofsson B, Pajusola K, von Euler G, et al. Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform. J Biol Chem 1996; 271: 19310–19317
   PubMed Web of Science ®Google Scholar
• Olofsson B, Pajulosa K, Kaipainen A, et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 1996; 93: 2576–2581
   PubMed Web of Science ®Google Scholar
• Yamada Y, Nezu J, Shimane M, et al. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics 1997; 42: 483–488
   PubMed Web of Science ®Google Scholar
• Sowter H M, Corps A N, Evans A L, et al. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab Invest 1997; 77: 607–614
   PubMed Web of Science ®Google Scholar
• Nicosia R F. What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis?. Am J Pathol 1998; 153: 11–16
   PubMed Web of Science ®Google Scholar
• Kukk E, Lymboussaki A, Taka S, et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 1996; 122: 3829–3837
   PubMed Web of Science ®Google Scholar
• Lymboussaki A, Partanen T A, Olofsson B, et al. Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am J Pathol 1998; 153: 395–403
   PubMed Web of Science ®Google Scholar
• Pajusola K, Aprelikova O, Pelicci G, et al. Signaling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors. Oncogene 1994; 9: 3545–3555
   PubMed Web of Science ®Google Scholar
• Joukov V, Sorsa T, Kumar V, et al. Proteolytic processing regulates receptor sensitivity and activity of VEGF-C. EMBO J 1997; 16: 3898–3911
   PubMed Web of Science ®Google Scholar
• Witzenbichler B, Asahara T, Murohara T, et al. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol 1998; 153: 381–394
   PubMed Web of Science ®Google Scholar
• Achen M G, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Roc Natl Acad Sci USA 1998; 95: 548–553
   PubMed Web of Science ®Google Scholar
• Salven P, Lymboussaki A, Helkkila P, et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 1998; 153: 103–108
   PubMed Web of Science ®Google Scholar
• Yamasaki M, Miyake A, Tagashira S, et al. Structure and expression of the rat mRNA encoding a novel member of the fibroblast growth factor family. J Biol Chem 1996; 271: 15918–15921
   PubMed Web of Science ®Google Scholar
• Smallwood P M, Munoz-Sanjuan I, Tong P, et al. Fibroblast growth factor (FGF) homologous factors: new members of the FGF family implicated in nervous system development. Proc Natl Acad Sci USA 1996; 93: 9850–9857
   PubMed Web of Science ®Google Scholar
• Coulier F, Pontarotti P, Roubin R, et al. Of worms and men: an evolutionary perspective on the fibroblast growth factor (FGF) and FGF receptor families. J Mol Evol 1997; 44: 43–56
   PubMed Web of Science ®Google Scholar
• Sato Y, Rifkin D B. Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J Cell Biol 1988; 107: 1199–1205
   PubMed Web of Science ®Google Scholar
• Rifkin D B, Moscatelli D. Recent developments in the cell biology of basic fibroblast growth factor. J Cell Biol 1989; 109: 1–6
   PubMed Web of Science ®Google Scholar
• Klein S, Giancotti F, Presta M, et al. Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells. Mol Biol Cell 1993; 4: 973–982
   PubMed Web of Science ®Google Scholar
• Hughes S E, Hall P A. The fibroblast growth factor and receptor multigene families. J Pathol 1993; 170: 219–221
   PubMed Web of Science ®Google Scholar
• Christofori G. The role of fibroblast growth factors in tumour progression and angiogenesis. Turnour Angiogenesis, R Bicknell, C E Lewis, N Ferrara. Oxford University Press, New York 1997; 201–237
   Google Scholar
• Klein S, Roghani M, Rifkin D B. Fibroblast growth factors as angiogenesis factors: new insights into their mechanism of action. Regulation of Angiogenesis, I D Goldberg, E M Rosen. Birkhauser Verlag, Boston 1997; 159–192
   Google Scholar
• Klagsburn M. Mediators of angiogenesis: the biological significance of basic fibroblast growth factor (bFGF)-heparin and he-paran sulfate interactions. Semin Cancer Biol 1992; 3: 81–87
   PubMedGoogle Scholar
• Taraboletti G, Belotti D, Borsotti P, et al. The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. Cell Growth Differ 1997; 8: 471–479
   PubMedGoogle Scholar
• Nguyen M, Watanabe H, Budson A E, et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancer. J Natl Cancer Inst 1994; 86: 356–361
   PubMed Web of Science ®Google Scholar
• Chodak G W, Hospelhom V, Judge S M, et al. Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res 1988; 48: 2083–2088
   PubMed Web of Science ®Google Scholar
• Dinney C PN, Fishbeck R, Singh R K, et al. Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol 1995; 154: 1532–1538
   Google Scholar
• Nanus D M, Schmitz-Drager B J, Motzer R J, et al. Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst 1993; 85: 1597–1599
   PubMed Web of Science ®Google Scholar
• Hori A, Sasada R, Matsutani E, et al. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 1991; 51: 6180–6184
   PubMed Web of Science ®Google Scholar
• Campbell S C, Volpert O V, Ivanovich M, et al. Molecular mediators of angiogenesis in bladder cancer. Cancer Res 1998; 58: 1298–1304
   PubMed Web of Science ®Google Scholar
• Dinney C PN, Bielenberg D R, Perrotte P, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-a administration. Cancer Res 1998; 58: 808–814
   PubMed Web of Science ®Google Scholar
• Kandel J, Bossy-Wetzel E, Radvanyi F, et al. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 1991; 66: 1095–1104
   PubMed Web of Science ®Google Scholar
• Anandappa S Y, Winstanley J HR, Leinster S, et al. Comparative expression of fibroblast growth factor mRNAs in benign and malignant breast disease. Br J Cancer 1994; 69: 772–776
   PubMed Web of Science ®Google Scholar
• Eguchi J, Nomata K, Kanda S, et al. Gene expression and immu-nohistochemical localization of basic fibroblast growth factor in renal cell carcinoma. Biochem Biophys Res Commun 1992; 183: 937–944
   PubMed Web of Science ®Google Scholar
• Luqmani Y A, Graham M, Coombes R C. Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer 1992; 66: 273–280
   PubMed Web of Science ®Google Scholar
• Takahashi J A, Mori H, Fukumoto M, et al. Gene expression of fibroblast growth factors in human gliomas and meningiomas: demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues. Roc Natl Acad Sci USA 1990; 87: 5710–5714
   PubMed Web of Science ®Google Scholar
• Saksela O, Moscatelli D, Sommer A, et al. Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 1988; 107: 743–751
   PubMed Web of Science ®Google Scholar
• Vlodavsky I, Folkman J, Sullivan R, et al. Endothelial cell-derived basic fibroblast growth factors: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci USA 1987; 84: 2292–2296
   PubMed Web of Science ®Google Scholar
• Bashkin P, Doctrow S, Klagsburn M, et al. Basic fibroblast growth factor binds to subendothelid extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 1989; 28: 1737–1743
   PubMed Web of Science ®Google Scholar
• O'Brien T, Cranston D, Fuggle S, et al. Two mechanisms of basic fibroblast growth factor-induced angiogenesis in bladder cancer. Cancer Res 1997; 57: 136–140
   PubMed Web of Science ®Google Scholar
• Pepper M S, Ferrara N, Orci L, et al. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992; 189: 824–831
   PubMed Web of Science ®Google Scholar
• Goto F, Goto K, Weindel K, et al. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest 1993; 69: 508–517
   PubMed Web of Science ®Google Scholar
• Asahara T, Bauters C, Zheng L P, et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995; 92(Suppl II)11–5–371
   Google Scholar
• Montesano R, Vassalli J-D, Baird A, et al. Basic fibroblast growth factor induces angiogenesis in vitro. Roc Natl Acad Sci USA 1986; 83: 7297–7301
   PubMed Web of Science ®Google Scholar
• Gospodarowicz D, Neufield G, Schweigerer L. Fibroblast growth factor: structural and biological properties. J Cell Physiol Suppl 1987; 5: 15–26
   PubMedGoogle Scholar
• Mignatti P, Tsuboi R, Robbins E, et al. In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. J Cell Biol 1989; 108: 671–682
   PubMed Web of Science ®Google Scholar
• Klagsbrun M, D'Amore P A. Regulators of angiogenesis. Annu Rev Physiol 1991; 53: 217–239
   PubMed Web of Science ®Google Scholar
• Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931–10934
   PubMed Web of Science ®Google Scholar
• Haimovitz-Friedman A, Balaban N, McLoughlin M, et al. Protein kinase C mediates basic fibroblast growth factor protection of endothelial cells against radiation-induced apoptosis. Cancer Res 1994; 54: 2591–2597
   PubMed Web of Science ®Google Scholar
• Fuks Z, Persaud R S, Alfieri A, et al. Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res 1994; 54: 2582–2590
   PubMed Web of Science ®Google Scholar
• Miyagawa K, Sakamoto H, Yoshida T, et al. hst-1 transforming protein: expression in silkworm cells and characterization as a novel heparin-binding growth factor. Oncogene 1988; 3: 383–389
   PubMed Web of Science ®Google Scholar
• Yoshida T, Ishimaru K, Sakamoto H, et al. Angiogenic activity of the recombinant hst-1 protein. Cancer Lett 1994; 83: 261–268
   PubMed Web of Science ®Google Scholar
• Pizette S, Batoz M, Hats H, et al. Production and functional characterization of human recombinant FGF-6 protein. Cell Growth Differ 1991; 2: 561–566
   PubMedGoogle Scholar
• Beckner M E, Liotta L A. Growth factors and cytokines in tumor invasion and metastasis. Growth Factors and Cytokines in Health and Disease, D LeRoith, C Bondy. JAI Press, Greenwich 1997; Vol. 3B: 381–437
   Google Scholar
• Dimitroff C J, Klohs W, Sharma A, et al. Evaluation of the effects of PDl 66285 and PD173074 on in vitro and in vivo angiogen-esis. Proc Am Assoc Cancer Res 1998; 39: 96, (abstract).
   Google Scholar
• Driscoll D, Steinkampf R, Hamby J, et al. Evaluation of tyrosine kinase inhibitors in vitro models of angiogenesis. Proc Am Assoc Cancer Res 1998; 39: 96, (abstract).
   Google Scholar
• Warren R S, Yuan H, Matli M R, et al. Induction of vascular en-dothelial growth factor by insulin-like growth factor l in colo-rectal carcinoma. J Biol Chem 1996; 271: 29483–29488
   PubMed Web of Science ®Google Scholar
• Grant M, Jerdan J, Merimee T J. Insulin-like growth factor-I modulates endothelial cell chemotaxis. J Clin Endocrinol Metab 1987; 65: 370–371
   PubMed Web of Science ®Google Scholar
• Nakao-Hayashi J, Ito H, Kanayasu T, et al. Stimulatory effects of insulin and insulin-like growth factor I on migration and tube formation by vascular endothelial cells. Atherosclerosis 1992; 92: 141–149
   PubMed Web of Science ®Google Scholar
• Rom W N, Basset P, Fells G A, et al. Alveolar macrophages release an insulin-like growth factor 1-type molecule. J Clin Invest 1988; 82: 1685–1693
   PubMed Web of Science ®Google Scholar
• Filkins J P. Endotoxin-enhanced secretion of macrophage insulin-like activity. J Reticuloendothel Soc 1980; 27: 507–511
   PubMedGoogle Scholar
• Singer C, Rasmussen A, Smith H S, et al. Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: Evidence for paracrine function. Cancer Res 1995; 55: 2448–2454
   PubMed Web of Science ®Google Scholar
• Kim K-W, Bae S-K, Lee O-H, et al. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res 1998; 58: 348–351
   PubMed Web of Science ®Google Scholar
• King G L, Goodman D, Buzney S, et al. Receptors and growth promoting effects of insulin and insulin-like growth factors on cells from bovine retinal capillary and aorta. J Clin Invest 1985; 75: 1028–1036
   PubMed Web of Science ®Google Scholar
• Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989; 342: 440–443
   PubMed Web of Science ®Google Scholar
• Stoker M, Gherardi E, Perryman M, et al. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987; 321: 239–242
   Google Scholar
• Montesano R, Matsumoto K, Nakamura T, et al. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 1991; 67: 901–908
   PubMed Web of Science ®Google Scholar
• Tsarfaty I, Resau J H, Rulong S, et al. The mer proto-oncogene receptor and luman formation. Science 1992; 257: 1258–1261
   PubMedGoogle Scholar
• Grant D S, Kleinman H K, Goldberg I, et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 1993; 90: 1937–1941
   PubMed Web of Science ®Google Scholar
• Rosen E M, Grant D S, Kleinman H K, . Scatter factor (hepatocyte growth factor) is a potent angiogenesis factor in vivo. Cell Behavior: Adhesion and Motility, G Jones, C Wigley, R Warn, et al. The Company of Biologists Limited, Cambridge 1993; 227–234
   Google Scholar
• Rosen E M, Nigam S K, Goldberg I D. Scatter factor and the c-met receptor: a paradigm for mesenchymal/epithelial interaction. J Cell Biol 1994; 127: 1783–1787
   PubMed Web of Science ®Google Scholar
• Rosen E M, Goldberg I D. Scatter factor and angiogenesis. Adv Cancer Res 1995; 67: 257–279
   PubMed Web of Science ®Google Scholar
• Lamszus K, Jin L, Fuchs A, et al. Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice. Lab Invest 1997; 76: 339–353
   PubMed Web of Science ®Google Scholar
• Zhau H, Pisters L, Hall M C, et al. Biomarkers associated with prostate cancer progression. J Cell Biochem Suppl 1994; 19: 208–216
   PubMedGoogle Scholar
• Naidu Y M, Rosen E M, Zitnick R, et al. Role of scatter factor in the pathogenesis of AIDS-related Kaposi sarcoma. Proc Natl Acad Sci USA 1994; 91: 5281–5285
   PubMed Web of Science ®Google Scholar
• Laterra J, Nam M, Rosen E, et al. Scatter factorlepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo. Lab Invest 1997; 76: 565–577
   PubMed Web of Science ®Google Scholar
• Montesano R, Soriano J V, Malinda K M, et al. Differential effects of hepatocyte growth factor isoforms on epithelial and endothelial tubulogenesis. Cell Growth Differ 1998; 9: 355–365
   PubMedGoogle Scholar
• Fang W, Hartmann N, Chow D T, et al. Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in Iiuman cancer. J Biol Chem 1992; 267: 25880–25897
   Google Scholar
• Laaroubi K, Delbe J, Vacherot F, et al. Mitogenic and in vitro angiogenic activity of human recombinant heparin affin regulatory peptide. Growth Factors 1994; 10: 89–98
   PubMed Web of Science ®Google Scholar
• Schulte A M, Wellstein A. Pleiotrophin and related molecules. Tnmour Angiogenesis, R Bicknell, C E Lewis, N Ferrara. Oxford University Press, New York 1997; 273–289
   Google Scholar
• Raulo E, Chernousov M A, Carey D J, et al. Isolation of a neusonal cell susrface receptor of heparin binding growth-associated molecule (HB-GAM). J Biol Chem 1994; 269: 12999–13004
   PubMed Web of Science ®Google Scholar
• Riegal A T, Wellstein A. The potential role of the heparinbinding growth factor pleiotrophin in breast cancer. Breast Cancer Res Treat 1994; 31: 309–314
   PubMed Web of Science ®Google Scholar
• Czubayko F, Riegel A T, Wellstein A. Ribozyme-targeting elucidates a direct role of pleiotrophin in tumor growth. J Biol Chem 1994; 269: 21358–21363
   PubMed Web of Science ®Google Scholar
• Tsutsui J-I, Kadomatsu K, Matsubara S, et al. A new family of heparin-binding growth/differentiation factors: increased mid-kine expression in Wilms' tumor and other human carcinomas. Cancer Res 1993; 53: 1281–1285
   PubMed Web of Science ®Google Scholar
• O'Brien T, Cranston D, Fuggle S, et al. The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res 1996; 56: 2515–2518
   PubMed Web of Science ®Google Scholar
• Koch A E, Polverini P J, Kunkel S L, et al. Interleukin-8 as a mac-rophage-derived mediator of angiogenesis. Science 1992; 258: 1798–1801
   PubMed Web of Science ®Google Scholar
• Stneter R M, Kunkel S L, Elner V M, et al. Interleukin-8 a corneal factor that induces neovascularization. Am J Pathol 1992; 141: 1279–1284
   PubMed Web of Science ®Google Scholar
• Moore B B, Arenberg D A, Strieter R M. The role of CXC chemo-kines in the regulation of angiogenesis in association with lung cancer. Trends Cardiovasc Med 1998; 8: 51–58
   PubMed Web of Science ®Google Scholar
• Smith D R, Polverini P J, Knnkel S L, et al. Inhibition of interleu-kin 8 attenuates angiogenesis in hronchogenic carcinoma. J Exp Med 1994; 179: 1409–1415
   PubMed Web of Science ®Google Scholar
• Strieter R M, Polverini P J, Arenberg D A, et al. Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J Leukocyte Biol 1995; 57: 752–762
   PubMed Web of Science ®Google Scholar
• Arenberg D A, Kunkel S L, Polverini P J, et al. Inhibition of in-terleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 1996; 97: 2792–2802
   PubMed Web of Science ®Google Scholar
• Kitadai Y, Haruma K, Sumii K, et al. Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am J Pathol 1998; 152: 93–100
   PubMed Web of Science ®Google Scholar
• Sankar S, Mahooti-Brooks N, Centrella M, et al. Expression of transforming growth factor type III receptor in vascular endothesial cells increases their responsiveness to transforming growth factor β2. J Biol Chem 1995; 270: 13567–13572
   PubMed Web of Science ®Google Scholar
• Shah M, Foreman D M, Ferguson M WJ. Neutralization of TGF-pi and TGF-β2 or exogenous addition of TGF-β3 to cutaneous rat wounds reduces scarring. J Cell Sci 1995; 108: 985–1002
   PubMed Web of Science ®Google Scholar
• Massague J, Attisano L, Wrana J L. The TGF-β family and its composite receptors. Trends Cell Biol 1994; 4: 172–176
   PubMedGoogle Scholar
• Kingsley D M. The TGF-β superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev 1994; 8: 133–146
   PubMed Web of Science ®Google Scholar
• Wrana J L, Attisano L, Wieser R, et al. Mechanism of activation of the TGF-β receptor. Nature 1994; 370: 341–347
   PubMed Web of Science ®Google Scholar
• Madri J A, Pratt B A, Tucker A M. Phenotypic modulation of endothelial cells by transforming growth factor β depends upon the composition and organization of the extracellular matrix. J Cell Biol 1988; 106: 1375–1384
   PubMed Web of Science ®Google Scholar
• Menvin J R, Anderson J M, Kocher O, et al. Transforming growth factor betal modulates extracellular matrix organization and cell-cell junctional complex formation during in vitro angiogenesis. J Cell Physiol 1990; 142: 117–128
   PubMed Web of Science ®Google Scholar
• Madri J A, Sankar S. The biphasic effects of transforming growth factors β in angiogenesis. Tumour Angiogenesis, R Bicknell, C E Lewis, N Ferrara. Oxford University Press, New York 1997; 239–249
   Google Scholar
• Xu J, Matsuzaki K, Mckeehan K, et al. Genomic structure and cloned cDNAs predict that four variants in the kinase domain of serine/threonine kinase receptors arise by alternative splicing and poly(A) addition. Proc Natl Acad Sci USA 1994; 91: 7957–7961
   PubMed Web of Science ®Google Scholar
• Antonelli-Orlidge A, Saunders K B, Smith S R, et al. An activated form of transforming growth factor β is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci USA 1989; 86: 454–4548
   Google Scholar
• Sato Y, Rifkin D B. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-β1-like molecule by plasmin during co-culture. J Cell Biol 1989; 109: 309–315
   PubMed Web of Science ®Google Scholar
• Schultz-Cheny S, Murphy-Ullrich J E. Thrombospondin causes activation of latent transforming growth factor-β secreted by endothelial cells by a novel mechanism. J Cell Biol 1993; 122: 923–932
   PubMed Web of Science ®Google Scholar
• Penttinen R P, Kobayashi S, Bornstein P. Transforming growth factor β increases mRNA for matrix proteins both in the presence and in the absence of changes in mRNA stability. Proc Natl Acad Sci USA 1988; 85: 1105–1108
   PubMed Web of Science ®Google Scholar
• Bobik A, Agrotis A, Little P J. Vascular-derived growth factors: potential role in the development of the tumour vasculature. Tumour Angiogenesis, R Bicknell, C E Lewis, N Ferrara. Oxford University Press, New York 1997; 169–184
   Google Scholar
• Falanga V, Qian S W, Danielpour D, et al. Hypoxia upregulates the synthesis of TGF-β1 by human dermal fibroblasts. J Invest Dermatol 1991; 97: 634–637
   PubMed Web of Science ®Google Scholar
• Kim S-J, Park K, Rudkin B B, et al. Nerve growth factor induces transcription of transforming growth factor-β1 through a specific promoter element in PC12 cells. J Biol Chem 1994; 269: 3739–3744
   PubMed Web of Science ®Google Scholar
• Kim S-J, Lee H-D, Robbins P D, et al. Regulation of transforming growth factor β1 gene expression by the product of the retinoblastoma-susceptibility gene. Proc Natl Acad Sci USA 1991; 88: 3052–3056
   PubMed Web of Science ®Google Scholar
• Lafyatis R, Lechleider R, Kim S-J, et al. Structural and functional characterization of the transforming growth factor β3 promoter. J Biol Chem 1990; 265: 19128–19136
   PubMed Web of Science ®Google Scholar
• Bang Y-J, Kim S-J, Danielpour D, et al. Cyclic AMP induces transforming growth factor β2 gene expression and growth arrest in the human androgen-independent prostate carcinoma cell line PC-3. Proc Natl Acad Sci USA 1992; 89: 3556–3560
   PubMed Web of Science ®Google Scholar
• Matsuno F, Haruta Y, Kondo M, et al. Induction of long-lasting complete regression of distinct preformed solid tumors by targeting endoglin of tumor vasculature. Proc Am Assoc Cancer Res 1998; 39: 97
   Google Scholar
• Schreiber A B, Winkler M E, Derynck R. Transforming growth factor-αa more potent angiogenic mediator than epidermal growth factor. Science 1986; 232: 1250–1253
   PubMed Web of Science ®Google Scholar
• Madtes D K, Raines E W, Sakariassen K S, et al. Induction of transforming growth factor-α in activated human alveolar macrophages. Cell 1988; 53: 285–293
   PubMed Web of Science ®Google Scholar
• Rappolee D A, Mark D, Banda M J, et al. Wound macrophages express TGF-α and other growth factors in vivo: analysis by mRNA phenotyping. Science 1988; 241: 708–712
   PubMed Web of Science ®Google Scholar
• Sato Y, Okamura K, Morimoto A, et al. Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cells in vitro. Exp Cell Res 1993; 204: 223–229
   PubMed Web of Science ®Google Scholar
• Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med 1987; 316: 379–385
   PubMed Web of Science ®Google Scholar
• Leibovich S J, Polverini P J, Shepard H M, et al. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α. Nature 1987; 329: 630–632
   PubMed Web of Science ®Google Scholar
• Scannell G, Waxman K, Kaml G J, et al. Hypoxia induces a buman macrophage cell line to release tumor necrosis factor-α and its soluble receptors in vitro. J Surg Res 1993; 54: 281–285
   PubMed Web of Science ®Google Scholar
• Jaattela M. Biologic activities and mechanisms of action of tumor necrosis factor-α/cachectin. Lab Invest 1991; 64: 724–742
   PubMed Web of Science ®Google Scholar
• Klein L M, Lavker R M, Matis W L, et al. Degradation of human mast cells induces an endothelial antigen central to leukocyte adhesion. Proc Natl Acad Sci USA 1989; 86: 8972–8976
   PubMed Web of Science ®Google Scholar
• Shalaby M R, Sundan A, Loetscher H, et al. Binding and regulation of cellular functions by monoclonal antibodies against human tumor necrosis factor receptors. J Exp Med 1990; 172: 1517–1520
   PubMed Web of Science ®Google Scholar
• Fajardo L F, Allison A C. Tumour necrosis factor α and angiogenesis. Tumour Angiogenesis, R Bicknell, C E Lewis, N Ferrara. Oxford University Press, New York 1997; 261–271
   Google Scholar
• Frater-Schroder M, Risau W, Hallmann R, et al. Tumor necrosis factor type α, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA 1987; 84: 5277–5281
   PubMed Web of Science ®Google Scholar
• Fajardo L F, Kwan H H, Kowalski J, et al. Dual role of tumor necrosis factor-α in angiogenesis. Am J Pathol 1992; 140: 539–544
   PubMed Web of Science ®Google Scholar
• van Hinsbergh V WM, van den Berg E A, Fiers W, et al. Tumor necrosis factor induces the production of urokinase-type plas-minogen activator by human endothelial cells. Blood 1990; 75: 1991–1998
   PubMed Web of Science ®Google Scholar
• Okamura K, Sato Y, Matsuda T, et al. Endogenous basic fibro-blast growth factor-dependent induction of collagenase and in-terleukin-6 in tumor necrosis factor-treated human microvascu-lar endothelial cells. J Biol Chem 1991; 266: 19162–19165
   PubMed Web of Science ®Google Scholar
• Niedbala M J, Picarella M S. Tumor necrosis factor induction of endothelial cell urokinase-type plasminogen activator mediated proteolysis of extracellular matrix and its antagonism by γ-inter-feron. Blood 1992; 79: 678–687
   PubMed Web of Science ®Google Scholar
• Leibovich S J, Polverini P J, Fong T W, et al. Production of angio-genic activity by human monocytes requires an L-arginine/nitric oxide-synthase-dependent effector mechanism. Proc Natl Acad Sci USA 1994; 91: 4190–4194
   PubMed Web of Science ®Google Scholar
• Holzman L B, Marks R M, Dixit V M. A novel immediate-early response gene of endothelium is induced by cytokines and encodes a secreted protein. Mol Cell Biol 1990; 10: 5830–5838
   PubMed Web of Science ®Google Scholar
• Pandey A, Shao H, Marks R M, et al. Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-α-induced angiogenesis. Science 1995; 268: 567–569
   PubMed Web of Science ®Google Scholar
• Robaye B, Mosselmans R, Fiers W, et al. Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cells in vitro. Am J Pathol 1991; 138: 447–453
   PubMed Web of Science ®Google Scholar
• Scbweigerer L, Malerstein B, Gospodarowicz D. Tumor necrosis factor inhibits the proliferation of cultured capillary endothelial cells. Biochem Biophys Res Commun 1987; 143: 997–1004
   PubMed Web of Science ®Google Scholar
• Naylor M S, Stamp G WH, Foulkes W D, et al. Tumor necrosis factor and its receptors in human ovarian cancer. J Clin Invest 1993; 91: 2194–2206
   PubMed Web of Science ®Google Scholar
• Pusztai L, Clover L M, Cooper K, et al. Expression of tumour necrosis factor α and its receptors in carcinoma of the breast. Br J Cancer 1994; 70: 289–292
   PubMed Web of Science ®Google Scholar
• Ross R, Glomset J, Kariya B, et al. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci USA 1974; 71: 1207–1210
   PubMed Web of Science ®Google Scholar
• Barrett T B, Gajdusek C M, Schwartz S M, et al. Expression of the sis gene by endothelial cells in culture and in vivo. Roc Natl Acad Sci USA 1984; 81: 6772–6774
   PubMed Web of Science ®Google Scholar
• Holmgren L, Glaser A, Heifer-Ohlsson S, et al. Angiogenesis during human extraembryonic development involves the spatio-temporal control of PDGF ligand and receptor gene expression. Development 1991; 113: 749–754
   PubMed Web of Science ®Google Scholar
• Liaw L, Schwartz S M. Comparison of gene expression in bovine aortic endothelium in vivo versus in vitro. Arterioscler Thromb 1993; 13: 985–993
   PubMedGoogle Scholar
• Bagavandoss P, Wilks J W. Specific inhibition of endothelial cell proliferation by thrombospondin. Biochem Biophys Res Commun 1990; 170: 867–872
   PubMed Web of Science ®Google Scholar
• Smits A, Hermansson M, Nister M, et al. Rat brain capillary endothelial cells express functional PDGF B-type receptors. Growth Factors 1989; 2: 1–8
   PubMed Web of Science ®Google Scholar
• Anan K, Morisaki T, Katano M, et al. Vascular endothelial growth factor and platelet-derived growth factor are potential an-giogenic and metastatic factors in human breast cancer. Surgery 1996; 119: 333–339
   PubMed Web of Science ®Google Scholar
• Gay C G, Winkles J A. Heparin-binding growth factor-1stimulation of human endotbelial cells induces platelet-derived growth factor A-chain gene expression. J Biol Chem 1990; 265: 3284–3292
   PubMed Web of Science ®Google Scholar
• Lauren J, Gunji Y, Alitalo K. Is angiopoietin-2 necessary for the initiation of tumor angiogenesis?. Am J Pathol 1998; 153: 1333–1339
   PubMed Web of Science ®Google Scholar
• Papapetropoulos A, Garcia-Cardena G, Dengler T J, et al. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest 1999; 79: 213–223
   PubMed Web of Science ®Google Scholar
• Suatmann A, Risau W, Plate K H. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblas-toma angiogenesis. Am J Pathol 1998; 153: 1459–1466
   PubMed Web of Science ®Google Scholar
• Sun C, McClain J, Thurston G, et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998; 282: 468–471
   PubMed Web of Science ®Google Scholar
• Sun C, Jones P F, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87: 1171–1180
   PubMed Web of Science ®Google Scholar
• Peters K G, Coogan A, Berry D, et al. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer 1998; 77: 51–56
   PubMed Web of Science ®Google Scholar
• Lin P, Polverini P, Dewhirst M, et al. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest 1997; 100: 2072–2078
   PubMed Web of Science ®Google Scholar
• Hatva E, Kaipainen A, Jaaskelainen J, et al. Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumours. Am J Pathol 1995; 146: 368–378
   PubMed Web of Science ®Google Scholar
• Kaipainen A, Vlaykova T, Hatva E, et al. Enhanced expression of the tie receptor tyrosine kinase messenger RNA in the vascular endothelium of metastatic melanomas. Cancer Res 1994; 54: 6571–6577
   PubMed Web of Science ®Google Scholar
• Salven P, Joensuu H, Heikkila P, et al. Endothelial tie growth factor receptor provides angiogenic marker for assessment of breast cancer angiogenesis. Br J Cancer 1996; 74: 69–72
   PubMed Web of Science ®Google Scholar
• Ishikawa F, Miyazono K, Hellman U, et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989; 338: 557–562
   PubMed Web of Science ®Google Scholar
• Miyazono K, Takaku F. Platelet-derived endothelid cell growth factor structure and function. Jpn Circulation J 1991; 55: 1022–1026
   PubMedGoogle Scholar
• Haraguchi M, Miyndera K, Uemura K, et al. Angiogenic activity of enzymes. Nature 1994; 368: 198
   PubMed Web of Science ®Google Scholar
• Moghaddam A, Zhang H-T, Fan T-PD, et al. Thymidine phos-phorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 1995; 92: 998–1002
   PubMed Web of Science ®Google Scholar
• Usuki K, Heldin N-E, Miyazono K, et al. Production of platelet-derived endothelial cell growth factor by normal and transformed human cells in culture. Proc Natl Acad Sci USA 1989; 86: 7427–7431
   PubMed Web of Science ®Google Scholar
• Yoshimura A, Kuwazuru Y, Furukawa T, et al. Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes, and tumors. Biochim Biopliys Acta 1990; 1034: 107–113
   PubMed Web of Science ®Google Scholar
• Reynolds K, Farzaneh F, Collins W P, et al. Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor. J Natl Cancer Inst 1994; 86: 1234–1238
   PubMed Web of Science ®Google Scholar
• Moghaddam A, Zhang H-T, Fan T-PD, et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 1995; 92: 998–1002
   PubMed Web of Science ®Google Scholar
• O'Brien T, Cranston D, Fuggle S, et al. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 1995; 55: 510–513
   PubMed Web of Science ®Google Scholar
• O'Brien T, Fox S B, Dickinson A J, et al. Expression of the angio-genic factor thymidine pbosphorylase/platelet-derived endothe-lial cell growth factor in primary bladder cancers. Cancer Res 1996; 56: 4799–4804
   PubMed Web of Science ®Google Scholar
• Takebayashi Y, Akiyama S-I, Akiba S, et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 1996; 88: 1110–1117
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Bucana C D, Liu W, et al. Platelet-derived endothe-lial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst 1996; 88: 1146–1151
   PubMed Web of Science ®Google Scholar
• Takebayashi Y, Yamada K, Miyadera K, et al. The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer 1996; 32A: 1227–1232
   PubMed Web of Science ®Google Scholar
• Eda H, Fujimoto K, Watanabe S-I, et al. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 1993; 32: 333–338
   PubMed Web of Science ®Google Scholar
• Schwartz E L, Wan E, Wang F-S, et al. Regulation of expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in human colon carcinoma cells. Cancer Res 1998; 58: 1551–1557
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Mackman N, Moons L, et al. Role of tissue factor in embryonic blood vessel development. Nature 1996; 383: 73–75
   PubMed Web of Science ®Google Scholar
• Contrino J, Hair G, Kreutzer D L, et al. In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease. Nat Med 1996; 2: 209–215
   PubMed Web of Science ®Google Scholar
• Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994; 94: 1320–1327
   PubMed Web of Science ®Google Scholar
• Shoji M, Abe K, Dillehay D, et al. Tissue factor (TF) regulates the expression of vascular endothelial growth factor (VEGF) in vitro and angiogenesis in vivo in human breast cancer and melanoma. Blood 1996; 88: 514a
   Google Scholar
• Shoji M, Abe K, Nawroth P P, et al. Molecular mechanisms linking thrombosis and angiogenesis in cancer. Trends Cardiovasc Med 1997; 7: 52–59
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis and tissue factor. Nat Med 1996; 2: 167–168
   PubMed Web of Science ®Google Scholar
• Camerer E, Kolsto A-B, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 1996; 81: 1–1
   PubMed Web of Science ®Google Scholar
• Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990; 172: 1535–1545
   PubMed Web of Science ®Google Scholar
• Huang X, Molema G, King S, et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997; 275: 547–550
   PubMed Web of Science ®Google Scholar
• Hynes R O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11–25
   PubMed Web of Science ®Google Scholar
• Cheresh D A. Integrins: structure, function, and biological properties. Adv Mol Cell Biol 1993; 6: 225–252
   Google Scholar
• Meredith J EJ, Fazeli B, Schwartz M A. The extracellular matrix as a cell survival factor. Mol Biol Cell 1993; 4: 953–961
   PubMed Web of Science ®Google Scholar
• Brooks P C, Montgomery A MP, Rosenfield M, et al. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157–1164
   PubMed Web of Science ®Google Scholar
• Re F, Zanetti A, Sironi M, et al. Inhibition of anchorage-dependent cell spreading triggers apoptosis in cultured human endothelial cells. J Cell Biol 1994; 127: 537–546
   PubMed Web of Science ®Google Scholar
• Montgomery A MP, Reisfeld R A, Cheresh D A. Integrin αvβ3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci USA 1994; 91: 8856–8860
   PubMed Web of Science ®Google Scholar
• Ruoslahti E, Reed J C. Anchorage dependence, integrins, and apoptosis. Cell 1994; 77: 477–478
   PubMed Web of Science ®Google Scholar
• Ruoslahti E. Stretching is good for a cell. Science 1997; 276: 1345–1346
   PubMed Web of Science ®Google Scholar
• Varner J A, Emerson D A, Juliano I U. Integrin α5β1 expression negatively regulates cell growth: reversal by attachment to fi-bronectin. Mot Biol Cell 1995; 6: 725–740
   PubMed Web of Science ®Google Scholar
• Davis G E, Camarillo C W. Regulation of endothelial cell morphogenesis by integrins, mechanical forces, and matrix guidance pathways. Exp Cell Res 1995; 216: 113–123
   PubMed Web of Science ®Google Scholar
• Friedlander M, Brooks P C, Shaffer R W, et al. Definition of two angiogenic pathways by distinct αv integrins. Science 1995; 270: 1500–1502
   PubMed Web of Science ®Google Scholar
• Swerlick R A, Brown E J, Xu Y, et al. Expression and modulation of the vitronectin receptor on human dermal microvascular endothelial cells. J Invest Dermatol 1992; 99: 715–722
   PubMed Web of Science ®Google Scholar
• Enenstein J, Waleh N S, Kramer R H. Basic FGF and TGF-β differentially modulate integrin expression of human microvascular endothelial cells. Exp Cell Res 1992; 203: 499–503
   PubMed Web of Science ®Google Scholar
• Leavesley D I, Schwartz M A, Rosenfeld M, et al. Integrin β1-and β3-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J Cell Biol 1993; 121: 163–170
   PubMed Web of Science ®Google Scholar
• Healy J M, Murayama O, Maeda T, et al. Peptide ligands for integrin αvβ3 selected from random phage display libraries. Biochemistry 1995; 34: 3948–3955
   PubMed Web of Science ®Google Scholar
• Brooks P C, Clark R AF, Cheresh D A. Requirement of vascular integrin αvβ3 for angiogenesis. Science 1994; 264: 569–571
   PubMed Web of Science ®Google Scholar
• Brooks P C, Stromblad S, Klemke R, et al. Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 1815–1822
   PubMed Web of Science ®Google Scholar
• Mohler T, Brooks P C, Mitjans F, et al. Antagonists of integrin αvβ3/αvβ 5: an anti-angiogenic strategy for the treatment of cancer. Proc Am Assoc Cancer Res 1998; 39: 97
   Google Scholar
• Nickols A, Carron C, Meyer D, et al. Inhibition of tumor growth and metastasis by an αvβ3 integrin antagonist. Proc Am Assoc Cancer Res 1998; 39: 97
   Google Scholar
• Arap W, Pasqualini R. Ruoslahti Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279: 377–380
   PubMed Web of Science ®Google Scholar
• Albelda S M, Oliver P D, Romer L H, et al. EndoCAM: a novel endothelial cell-cell adhesion molecule. J Cell Biol 1990; 110: 1227–237
   PubMed Web of Science ®Google Scholar
• Madri J A, Bell L, Merwin J R. Modulation of vascular cell behavior by transforming growth factors β. Mol Reprod Dev 1992; 32: 121–126
   PubMed Web of Science ®Google Scholar
• DeLisser H M, Yan H C, Newman P J, et al. Platelet/endothelial cell adhesion molecule- 19931(CD31)-mediated cellular aggregation involves cell surface glycosaminoglycans. J Biol Chem, 268: 16037–16046
   PubMed Web of Science ®Google Scholar
• Piali L, Hammel P, Uherek C, et al. CD3l/PECAM-1 isaligand for αvβ3 integrin involved in adhesion of leukocytes to endothe-lium. J Cell Biol 1995; 130: 451–460
   PubMed Web of Science ®Google Scholar
• DeLisser H M, Christofidou-Solomidou M, Strieter R M, et al. Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol 1997; 151: 671–677
   PubMed Web of Science ®Google Scholar
• DeLisser H M, Baldwin H S, Albelda S M. Platelet endothelial cell adhesion molecule 1 (PECAM-1/CD31): a multifunctional vascular cell adhesion molecule. Trends Cardiovasc Med 1997; 7: 203–210
   PubMed Web of Science ®Google Scholar
• Kim C S, Wang T, Madri J A. Platelet endothelial cell adhesion molecule-1 expression modulates endothelial migration in vitro. Lab Invest 1998; 78: 583–590
   PubMed Web of Science ®Google Scholar
• Madri J A, Williams S K, Wyatt T, et al. Capillary endothelial cell cultures: phenotypic modulation by matrix components. J Cell Biol 1983; 97: 153–165
   PubMed Web of Science ®Google Scholar
• Basson C T, Knowles W J, Bell L, et al. Spatiotemporal segration of endothelial cell integrin and nonintegrin extracellular matrix-binding proteins during adhesion events. J Cell Biol 1990; 110: 789–801
   PubMed Web of Science ®Google Scholar
• Chen C, Mrksich M, Huang S, et al. Geometric control of cell life and death. Science 1997; 276: 1425–1428
   PubMed Web of Science ®Google Scholar
• Ingber D E. Extracellular matrix as a solid-state regulator in angiogenesis: identification of new targets for anti-cancer therapy. Semin Cancer Biol 1992; 3: 57–63
   PubMedGoogle Scholar
• Herbst T J, McCarthy J B, Tsilibary E C, et al. Differential effects of laminin, intact type IV collagen, and specific domains of type IV collagen on endothelial cell adhesion and migration. J Cell Biol 1988; 106: 1365–1373
   PubMed Web of Science ®Google Scholar
• Bowersox J C, Sorgente N. Chemotaxis of aortic endothelial cells in response to fibronectin. Cancer Res 1982; 42: 2547–2551
   PubMed Web of Science ®Google Scholar
• Form D M, Pratt B M, Madri J A. Endothelial cell proliferation during angiogenesis in vitro modulation by basement membrane components. Lab Invest 1986; 55: 521–530
   PubMed Web of Science ®Google Scholar
• Madri J A, Pratt B A. Endothelial cell-matrix interactions: In vitro models of angiogenesis. J Histochem Cytochem 1986; 34: 85–91
   PubMed Web of Science ®Google Scholar
• Kubota Y, Kleinman H K, Martin G R, et al. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol 1988; 107: 1589–1598
   PubMed Web of Science ®Google Scholar
• Schnaper H W, Kleinman H K, Grant D S. Role of laminin in endothelial cell recognition and differentiation. Kidney Int 1993; 43: 20–25
   PubMed Web of Science ®Google Scholar
• Kleinman H K, Weeks B S, Schnaper H W, et al. The laminins: a family of basement membrane glycoproteins important in cell differentiation and tumor metastases. Vitam Horm 1993; 47: 161–186
   PubMed Web of Science ®Google Scholar
• Kleinman H K, McGarvey M L, Liotta L A, et al. Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. Biochemistry 1982; 21: 6188–6193
   PubMed Web of Science ®Google Scholar
• Vukicevic S, Kleinman H K, Luyten F P, et al. Identification of multiple active growth factors in basement membrane Matrigel suggests caution in interpretation of cellular activity related to extracellular matrix components. Exp Cell Res 1992; 202: 1
   PubMed Web of Science ®Google Scholar
• Grant D S, Kleinman H. Regulation of capillary formation by laminin and other components. Regulation of Angiogenesis, I D Goldberg, E M Rosen. Birkhauser Verlag, Boston 1997; 317–333
   Google Scholar
• Iruela-Arispe M L, Hasselaar P, Sage H. Differential expression of extracellular proteins is correlated with angiogenesis in vitro. Lab Invest 1991; 64: 174–186
   PubMed Web of Science ®Google Scholar
• Iruela-Arispe M L, Diglio C A, Sage E H. Modulation of extracellular matrix proteins by endothelial cells undergoing angiogenesis in vitro. Arteriosclerosis Thromb 1991; 11: 805–815
   PubMedGoogle Scholar
• Tokida Y, Aratani Y, Morita A, et al. Production of two variant laminin forms by endothelial cells and shift of their relative levels by angiostatic steroids. J Biol Chem 1990; 265: 18123–18129
   PubMed Web of Science ®Google Scholar
• Folkman J, Ingber D. Inhibition of angiogenesis. Semin Cancer Biol 1992; 3: 89–96
   PubMedGoogle Scholar
• Maragoudakis M E, Tsopanoglou N, Haralabopoulos G, . Regulation of angiogenesis: the role of protein kinase, nitric oxide, thrombin and basement membrane synthesis. Angiogenesis Molecular Biology, Clinical Aspects, M E Maragoudakis, P M Gullino, P I Lelkes, et al. Plenum Press, New York 1994; Vol. 263: 125–134
   Google Scholar
• Boehm T, Fohan J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 335–336
   PubMedGoogle Scholar
• Dhanabal M, Ramchandran R, Volk R, et al. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res 1999; 59: 189–197
   PubMed Web of Science ®Google Scholar
• Zagzag D, Friedlander D R, Miller D C, et al. Tenascin expression in astrocytomas correlates with angiogenesis. Cancer Res 1995; 55: 907–914
   PubMed Web of Science ®Google Scholar
• Zagzag D, Friedlander D R, Dosik J, et al. Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res 1996; 56: 182–189
   PubMed Web of Science ®Google Scholar
• MacDonald T J, Laug W E. Migration of human brain tumor cells and human brain endothelial cells on tenascin requires the integrin αvβ 3: a unifying model for brain tumor invasion and angiogenesis. Proc Am Assoc Cancer Res 1998; 39: 497
   Google Scholar
• Sage H, Tupper J, Bramson R. Endothelial cell injury in vitro is associated with increased secretion of an M, 43,000 glycoprotein ligand. J Cell Physiol 1986; 127: 373–387
   PubMed Web of Science ®Google Scholar
• Sage H, Vernon R B, Deckner J, et al. Distribution of the calcium-binding protein SPARC in tissues of embryonic and adult mice. J Histochem Cytochem 1989; 37: 819–829
   PubMed Web of Science ®Google Scholar
• Lane T F, Iruela-Arispe M L, Johnson R S, et al. SPARC is a source of copper-binding peptides that stimulate angiogenesis. J Cell Biol 1994; 125: 929–943
   PubMed Web of Science ®Google Scholar
• Sage H, Vernon R B, Funk S E, et al. SPARC, a secreted protein associated with cellular proliferation, inhibits cell spreading in vitro and exhibits Ca2+-dependent binding to the extracellular matrix. J Cell Biol 1989; 109: 341–356
   PubMed Web of Science ®Google Scholar
• Gilles C, Bassuk J A, Pulyaeva H, et al. SPARClOsteonectin induces matrix metallproteinase 2 activation in human breast cancer cell lines. Cancer Res 1998; 58: 5529–5536
   PubMed Web of Science ®Google Scholar
• Beckner M E, Krutzsch H C, Stracke M L, et al. Identification of a new immunoglobulin superfamily protein expressed in blood vessels with a heparin-binding consensus sequence. Cancer Res 1995; 55: 2140–2149
   PubMed Web of Science ®Google Scholar
• Beckner M E, Liotta L A. AAMP, a conserved protein with immunoglobulin and WD40 domains, regulates endothelial tube formation in vitro. Lab Invest 1996; 75: 97–107
   PubMed Web of Science ®Google Scholar
• Beckner M E, Peterson V A, Moul D E. Angio-associated migratory cell protein is expressed as an extracellular protein in vitro by blood vessel-associated mesenchymal cells. Microvasc Res 1999; 57: 347–352
   PubMed Web of Science ®Google Scholar
• Beckner M E, Baylis C, Jagannathan S, et al. Antibody to angio-associated migratory cell protein (anti-rAAMP) inhibits angiogenesis, (submitted)
   Google Scholar
• Beckner M E, Peterson V A, Todd J H, et al. Angio-associated migratory cell protein is expressed in transformed and malignant human cells. Proc Am Assoc Cancer Res 1998; 39: 42
   Google Scholar
• Ropponen K, Tammi M, Parkkinen J, et al. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res 1998; 58: 342–347
   PubMed Web of Science ®Google Scholar
• Feinberg R N, Beehe D C. Hyaluronate in vasculogenesis. Science 1983; 220: 1177–1179
   PubMed Web of Science ®Google Scholar
• West D C, Hampson I N, Arnold F, et al. Angiogenesis induced by degradation products of hyaluronic acid. Science 1985; 228: 1324–1326
   PubMed Web of Science ®Google Scholar
• West D C, Kumar S. The effect of hyaluronate and its oligosac-charides on endothelial cell proliferation and monolayer integrity. Exp Cell Res 1989; 183: 179–196
   PubMed Web of Science ®Google Scholar
• Sattar A, Rooney P, Kumar S, et al. Application of angiogenic oligosaccharides of hyaluronan increases blood vessel numbers in rat skin. J Invest Dermatol 1994; 103: 576–579
   PubMed Web of Science ®Google Scholar
• Montesano R, Kumar S, Orci L, et al. Synergistic effect of hyaluronan oligosaccharides and vascular endothelial growth factor on angiogenesis in vitro. Lab Invest 1996; 75: 249–262
   PubMed Web of Science ®Google Scholar
• Rooney P, Wang M, Kumar P, et al. Angiogenic oligosaccharides of hyaluronan enhance the production of collagens by endothelial cells. J Cell Sci 1993; 105: 213–218
   PubMed Web of Science ®Google Scholar
• Slevin M, Krupinski J, Kumar S, et al. Angiogenic oligosaccharides of hyaluronan induce protein tyrosine kinase activity in endothelial cells and activate a cytoplasmic signal transduction pathway resulting in proliferation. Lab Invest 1998; 78: 987–1003
   PubMed Web of Science ®Google Scholar
• Kumar S, Ponting J, Rooney P, . Hyaluronan and angiogenesis: molecular mechanisms and clinical applications. Angiogenesis: Molecular Biology, Clinical Aspects, M E Maragoudakis, P M Gullino, P I Lelkes, et al. Plenum Press, New York 1994; 219–231
   Google Scholar
• Lokeshwar V B, Obek C, Soloway M S, et al. Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res 1997; 57: 773–777
   PubMed Web of Science ®Google Scholar
• Halfter W, Dong S, Schurer B, et al. Collagen XVIII is a basement membrane heparan sulfate proteoglycan. J Biol Chem 1998; 273: 25404–25412
   PubMed Web of Science ®Google Scholar
• Bashkin P, Razin E, Eldor A, et al. Degranulating mast cells secrete an endoglycosidase that degrades heparan sulfate in sub-endothelial extracellular matrix. Blood 1990; 75: 2204–2212
   PubMed Web of Science ®Google Scholar
• Folkman J, Weisz P B, Joullie M M, et al. Control of angiogenesis with synthetic heparin substitutes. Science 1989; 243: 1490–1493
   PubMed Web of Science ®Google Scholar
• Hanis A L, Fox S, Bicknell R, et al. Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer. Cancer 1994; 74: 1021–1025
   PubMed Web of Science ®Google Scholar
• O'Reilly M S, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277–285
   PubMed Web of Science ®Google Scholar
• Aviezer D, Hecht D, Safran M, et al. Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell 1994; 79: 1005–1013
   PubMed Web of Science ®Google Scholar
• Dvorak H F, Dvorak A M, Manseau E J, et al. Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fihroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in Line 1 tumor regression. J Natl Cancer Inst 1979; 62: 1459–1472
   PubMed Web of Science ®Google Scholar
• Dvorak H F, Harvey V S, Estrella P, et al. Fibrin containing gels induce angiogenesis. Lab Invest 1987; 57: 673–686
   PubMed Web of Science ®Google Scholar
• Shoji M, Hancock W W, Abe K, et al. Activation of coagulation and angiogenesis in cancer. Am J Pathol 1998; 152: 399–411
   PubMed Web of Science ®Google Scholar
• Qi J, Kreutzer D L. Fibrin activation of vascular endothelial cells. J Immunol 1995; 155: 867–876
   PubMed Web of Science ®Google Scholar
• Walz D A, Fenton J W. The role of thrombin in tumor cell metastasis. Invasion Metast 1995; 14: 303–308
   Google Scholar
• Mignatti P, Rifkin D B. Plasminogen activators and matrix metal-loproteinases in angiogenesis. Enzyme Protein 1996; 49: 117–137
   PubMedGoogle Scholar
• Liotta L A, Steeg P S, Stetler-Stevenson W G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327–336
   PubMed Web of Science ®Google Scholar
• Pepper M S, Montesano R, Mandriota S J, et al. Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein 1996; 49: 138–162
   PubMedGoogle Scholar
• Matrisian L M. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990; 6: 121–125
   PubMed Web of Science ®Google Scholar
• Stetler-Stevenson W G, Hewitt R, Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 1996; 7: 147–154
   PubMed Web of Science ®Google Scholar
• Mignatti P, Riflcin D B. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 73: 161–195
   PubMed Web of Science ®Google Scholar
• Chapman M A, Stone O L. Co-operation between plasmin and elastase in elastin degradation by intact murine macrophages. Biochem J 1984; 222: 721–728
   PubMed Web of Science ®Google Scholar
• Blei F, Wilson E L, Mignatti P, et al. Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol 1993; 155: 568–578
   PubMed Web of Science ®Google Scholar
• Moses M A, Langer R. A metalloproteinase inhibitor as an inhibitor of neovascularization. J Cell Biochem 1991; 47: 230–235
   PubMed Web of Science ®Google Scholar
• Wolff J EA, Guerin C, Laterra J, et al. Dexamethasone reduces vascular density and plasminogen activator activity in 9L rat brain tumors. Brain Res 1993; 604: 79–85
   PubMed Web of Science ®Google Scholar
• Itoh T, Tanioka M, Yoshida H, et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998; 58: 1048–1051
   PubMed Web of Science ®Google Scholar
• Fihbi G, Caldini R, Chevanne M, et al. Urokinase-dependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonucleotides against the urokinase receptor. Lab Invest 1998; 78: 1109–1119
   PubMed Web of Science ®Google Scholar
• Pollack R, Rifkin D. Actin-containing cables within anchorage-dependent rat embryo cells are dissociated by plasmin and tryp-sin. Cell 1975; 6: 495–506
   Web of Science ®Google Scholar
• Pepper M S, Belin D, Montesano R, et al. Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. J Cell Biol 1990; 111: 743–755
   PubMed Web of Science ®Google Scholar
• Lamoreaux W J, Fitzgerald M EC, Reiner A, et al. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 1998; 55: 29–42
   PubMed Web of Science ®Google Scholar
• Chen Z-Q, Fisher F U, Riggs C W, et al. Inhibition of vascular endothelial growth factor-induced endothelial cell migration by ETSl antisense oligonucleotides. Cancer Res 1997; 57: 2013–2019
   PubMed Web of Science ®Google Scholar
• Rasmussen H S, McCann P P. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 1997; 75: 69–75
   PubMed Web of Science ®Google Scholar
• Chambers A F., Wylie S, MacDonald I C, et al. The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells. Proc Am Assoc Cancer Res 1998; 39: 83
   Google Scholar
• Gopurala B, Siegal G P, Zhang M, et al. A novel synthetic dipep-tide inhibits tumor invasion and angiogenesis. Proc Am Assoc Cancer Res 1998; 39: 44
   Google Scholar
• Riviere M, Alaoui-Jamali M, Falardeau P, et al. Neovastat: an inhibitor of angiogenesis with anti cancer activity. Proc Am Assoc Cancer Res 1998; 39: 46
   Google Scholar
• O'Reilly M S, Holmgren L, Chen C, et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689–692
   PubMed Web of Science ®Google Scholar
• Tanaka T, Cao Y, Folkman J, et al. Viral vector-targeted antian-giogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res 1998; 58: 3362–3369
   PubMed Web of Science ®Google Scholar
• O'Reilly M S, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315–328
   PubMed Web of Science ®Google Scholar
• Gorski D H, Mauceri H J, Salloum R M, et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 1998; 58: 5686–5689
   PubMed Web of Science ®Google Scholar
• Jendraschak E, Sage E H. Regulation of angiogenesis by SPARC and angiostatin: implications for tumor cell biology. Semin Cancer Biol 1996; 7: 139–146
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis and angiogenesis inhibition: an overview. Regulation of Angiogenesis, I D Goldberg, E M Rosen. Birkhauser Verlag, Boston 1997; 1–8
   Google Scholar
• O'Reilly M S. Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. Regulation of Angiogenesis, I D Goldberg, E M Rosen. Birkhauser Verlag, Boston 1997; 273–294
   Google Scholar
• Bachelot T, Pawliuk R, Treilleux I, et al. Retrovirus-mediated gene transfer of an angiostatin-endostatin fusion protein with enhanced anti-tumor properties in vivo. Proc Am Assoc Cancer Res 1998; 39: 271
   Google Scholar
• Thomsen L, Lawton F G, Knowles R G, et al. Nitric oxide syn-thase activity in human gynecological cancer. Cancer Res 1994; 54: 1352–1354
   PubMed Web of Science ®Google Scholar
• Thomsen L L, Miles D W, Happerfield L, et al. Nitric oxide syn-thase activity in human breast cancer. Br J Cancer 1995; 72: 41–44
   PubMed Web of Science ®Google Scholar
• Cobbs C S, Brennan J E, Aldape K D, et al. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res 1995; 55: 727–730
   PubMed Web of Science ®Google Scholar
• Ambs S, Merriam W G, Bennett W P, et al. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res 1998; 58: 334–341
   PubMed Web of Science ®Google Scholar
• Jenkins D C, Charles I G, Thomsen L L, et al. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA 1995; 92: 4392–4396
   PubMed Web of Science ®Google Scholar
• Maeda H, Noguchi Y, Sato K, et al. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn J Cancer Res 1994; 85: 331–334
   PubMedGoogle Scholar
• Tozer G M, Prise V E, Chaplin D J. Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. Cancer Res 1997; 57: 948–955
   PubMed Web of Science ®Google Scholar
• Dimmeler S, Haendeler J, Nehls M, et al. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1β-con-verting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. J Exp Med 1997; 185: 601–607
   PubMed Web of Science ®Google Scholar
• Tzeng E, Kim Y-M, Pitt B R, et al. Adenoviral transfer of the inducible nitric oxide synthase gene blocks endothelial cell apoptosis. Surgery 1997; 122: 255–263
   PubMed Web of Science ®Google Scholar
• Murrell G AC, Jang D, Williams R J. Nitric oxide activates metal-loprotease enzymes in articular cartilage. Biochem Biophys Res Commun 1995; 206: 15–21
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Meng S P, Ramasamy S, et al. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. J Clin Invest 1996; 98: 2572–2579
   PubMed Web of Science ®Google Scholar
• Tamura T, Nakanishi T, Kimura Y, et al. Nitric oxide mediates interleukin-1-induced matrix degradation and basic fibroblast growth factor release in cultured rabbit articular chondrocytes: a possible mechanism of pathological neovascularization in arthritis. Endocrinology 1996; 137: 3729–3737
   PubMed Web of Science ®Google Scholar
• Thomsen L L, Scott J MJ, Topley P, et al. Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400W, a novel inhibitor. Cancer Res 1997; 57: 3300–3304
   PubMed Web of Science ®Google Scholar
• Melillo G, Musso T, Sica A, et al. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 1995; 182: 1683–1693
   PubMed Web of Science ®Google Scholar
• Znche M, Morhidelli L, Choudhuri R, et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997; 99: 2625–2634
   PubMed Web of Science ®Google Scholar
• Noiri E, Lee E, Testa J, et al. Podokinesis in endothelial cell migration: role of nitric oxide. Am J Physiol 1998; 274: C236–C244
   PubMed Web of Science ®Google Scholar
• Babaei S, Teichert-Kuliszewska K, Monge J-C, et al. Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor. Circ Res 1998; 82: 1007–1015
   PubMed Web of Science ®Google Scholar
• Ziche M, Morbidelli L, Mantelli L, . The proliferative effect of substance P on capillary endothelial cells is mediated by nitric oxide. Angiogenesis: Molecular Biology, Clinical Aspects, M E Maragoudakis, P M Gullino, P I Lelkes, et al. Plenum Press, New York 1994; 91–101
   Google Scholar
• Spisni E, Tomasi V. Involvement of prostanoids in angiogenesis. Tumour Angiogenesis, R Bicknell, C E Lewis, N Ferrara. Oxford University Press, New York 1997; 291–300
   Google Scholar
• Hla T. Early response genes in endothelial cells. Angiogenesis: Molecular Biology, Clinical Aspects, M E Maragoudakis, P M Gullino, P I Lelkes. Series A, Plenum Press, New York 1994; Vol. 263: 67–72
   Google Scholar
• Allison A C, Kowalski W J. Prostaglandins as transducers of proliferation signals in microvascular endothelial cells and the pharmacological control of angiogenesis. Vascular Endothelium Receptors and Transduction Mechanisms, J D Catravas, C N Gillis. Plenum Press, US Ryan, New York 1988; 99–110
   Google Scholar
• Smith W L, Meade E A, DeWitt D L. Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann NY Acad Sci 1994; 744: 50–57
   PubMed Web of Science ®Google Scholar
• Harada S-I, Nagy J A, Sullivan K A, et al. Induction of vascular endothelial growth factor expression by prostaglandin El and E, in osteoblasts. J Clin Invest 1994; 93: 2490–2496
   PubMed Web of Science ®Google Scholar
• Spisni E, Bartolini G, Orlandi M, et al. Prostacyclin (PG12) synthase is a constitutively expressed enzyme in human endothelial cells. Exp Cell Res 1995; 219: 507–513
   PubMed Web of Science ®Google Scholar
• Pearson I D, May M J. Regulation of endothelial cell function by cytokines. Immunological Aspects of the Vascular Endothelium, C OS Savage, J D Pearson. Cambridge University Press, Cambridge 1995; 20–42
   Google Scholar
• Shaul P W, Campbell W B, Farrar M A, et al. Oxygen modulates prostacyclin synthesis in ovine fetal pulmonary arteries by an effect on cyclooxygenase. J Clin Invest 1992; 90: 2147–2155
   PubMed Web of Science ®Google Scholar
• Brannon T S, North A J, Wells L B, et al. Prostacyclin synthesis in ovine pulmonary artery is developmentally regulated by changes in cyclooxygenase-1 gene expression. J Clin Invest 1994; 93: 2230–2235
   PubMed Web of Science ®Google Scholar
• Gao X, Grignon D J, Chbihi T, et al. Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology 1995; 46: 227–237
   PubMed Web of Science ®Google Scholar
• Tang D G, Renaud C, Stojakovic S, et al. 1995 12(S)-HETE is a mito-genic factor for microvascular endothelial cells: its potential role in angiogenesis. Biochem Biophys Res Commun, 211: 462–468
   PubMed Web of Science ®Google Scholar
• Tang D G, Diglio C A, Bazaz R, et al. Transcriptional activation of endothelial cell integrin αv by protein kinase C activator 12(S)-HETE. J Cell Sci 1995; 108: 2629–2644
   PubMed Web of Science ®Google Scholar
• Honn K V, Tang D G, Grossi I, et al. Tumor cell-derived 12(S)-hydroxyeicosatetraenoic acid induces microvascular endothelial cell retraction. Cancer Res 1994; 54: 565–574
   PubMed Web of Science ®Google Scholar
• Nie D, Hillman G G, Geddes T, et al. Platelet-type 12-lipoxygen-ase in a human prostate carcinoma stimulates angiogenesis and tumor growth. Cancer Res 1998; 58: 4047–4051
   PubMed Web of Science ®Google Scholar
• Kinsella J L, Grant D S, Weeks B S, et al. Protein kinase C regulates endothelial cell tube formation on basement membrane matrix, Matrigel. Exp Cell Res 1992; 199: 56–62
   PubMed Web of Science ®Google Scholar
• Seymour L W, Shoaibi M A, Martin A, et al. Vascular endothelial growth factor stimulates protein kinase C-dependent phospholi-pase D activity in endothelial cells. Lab Invest 1996; 75: 427–437
   PubMed Web of Science ®Google Scholar
• Fen J W, Strydom D J, Lobb R R, et al. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry 1985; 24: 5480–5486
   PubMed Web of Science ®Google Scholar
• Weiner H L, Weiner L H, Swain J L. Tissue distribution and developmental expression of the messenger RNA encoding angiogenin. Science 1987; 237: 280–282
   PubMed Web of Science ®Google Scholar
• Jackson D, Volpert O V, Bouck N, et al. Stimulation and inhibition of angiogenesis by placental proliferin and proliferin-related protein. Science 1994; 266: 1581–1584
   PubMed Web of Science ®Google Scholar
• Haudenschild C C, Klibaner M I. Nonpeptide angiogenesis factors. Angiogenesis Mechanisms and Pathobiology, D B Riflcin, M Klagsburn. Cold Spring Harbor Laboratory, Cold Spring Harbor 1987; 78–84
   Google Scholar
• Montrucchio G, Sapino A, Bussolati B, et al. Potential angiogenic role of platelet-activating factor in human breast cancer. Am J Pathol 1998; 153: 1589–1596
   PubMed Web of Science ®Google Scholar
• Fenselau A. Tumor and related angiogenesis factors. Growth and Maturation Factors, G Guroff. John Wiley & Sons, New York 1984; 87–129
   Google Scholar
• Vallee B L, Riordan J F, Lobb R R, et al. Tumor-derived angiogenesis factors from rat Walker 256 carcinoma: an experimental investigation and review. Experientia 1985; 41: 1–15
   PubMedGoogle Scholar
• Albini A, Benelli R, Presta M, et al. HIBV-tat protein is a hepa-rin-binding angiogenic growth factor. Oncogene 1996; 12: 289–297
   PubMed Web of Science ®Google Scholar